News

Intra-Cellular Therapies Reports Progress on CAPLYTA for MDD

Intra-Cellular Therapies Reports Progress on CAPLYTA for MDD

Intra-Cellular Therapies Advances CAPLYTA for Major Depressive Disorder

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is making significant strides in the field of mental health treatment with the recent submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for CAPLYTA (lumateperone). This innovative approach aims to enhance treatment options for adults dealing with Major Depressive Disorder (MDD), particularly as an adjunctive therapy with existing antidepressants.

Positive Clinical Study Outcomes

The decision to file the sNDA stems from promising results obtained from pivotal Studies 501 and 502. These studies showcase CAPLYTA’s robust antidepressant efficacy, confirming its favorable safety and tolerability profile. As noted by Dr. Suresh Durgam, Executive Vice President and Chief Medical Officer, the need for effective treatments is vital, as more than half of patients do not achieve satisfactory results with antidepressants alone.

Understanding Major Depressive Disorder

MDD is a widespread mood disorder, affecting millions of adults annually in the United States. Symptoms such as persistent sadness, hopelessness, and loss of interest significantly impair the quality of life for those afflicted. Astonishingly, approximately two-thirds of depression patients do not find relief with first-line treatments, underscoring the necessity for additional efficacious options like CAPLYTA.

Details of the Studies and Findings

Study 501 and Study 502 were designed as global, double-blind, placebo-controlled trials, primarily targeting individuals diagnosed with MDD per the DSM-5 criteria and who experienced insufficient response to ongoing antidepressant treatments. Results demonstrated notable efficacy in reducing symptoms, reflected by significant improvements in the Montgomery-Asberg Depression Rating Scale (MADRS).

CAPLYTA’s Role and Efficacy

CAPLYTA has shown effectiveness when used in combination with an antidepressant, achieving a substantial separation of 4.9 points in Study 501 and 4.5 points in Study 502 compared to placebo. Moreover, the safety profile highlighted that adverse effects were comparable to placebo, suggesting CAPLYTA's potential as a first-choice treatment for those not responding adequately to current therapies.

Exploring Safety and Tolerability

The pooled safety data evaluated side effects, finding several reported at a rate exceeding 5% for lumateperone compared to placebo. These included dizziness, dry mouth, somnolence, and fatigue. Notably, metabolic changes and weight variations were aligned with placebo rates, and the incidence of extrapyramidal symptoms remained low, highlighting CAPLYTA's advantageous profile in treating MDD.

Intra-Cellular Therapies’ Commitment to Innovation

Intra-Cellular Therapies is committed to advancing health solutions based on groundbreaking research that enhances our understanding of cellular effects on mental health. With ongoing studies investigating lumateperone's potential in various psychiatric and neurological disorders, this dedication brings hope to patients and families grappling with these complex conditions.

About CAPLYTA

CAPLYTA, which is already FDA-approved for schizophrenia and bipolar depression, showcases an intriguing mechanism of action that is still being fully understood. Its combination of actions at central serotonin 5-HT2A and dopamine D2 receptors indicates a multifaceted approach to psychiatric treatment, reinforcing the company’s commitment to pioneering mental health therapies.

Frequently Asked Questions

What is CAPLYTA and what conditions does it treat?

CAPLYTA is an atypical antipsychotic indicated for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder, and is under review for adjunctive therapy in MDD.

What were the outcomes of Studies 501 and 502?

Both studies demonstrated CAPLYTA's significant efficacy in treating MDD, showcasing improved scores on the MADRS scale and a favorable safety profile.

How does CAPLYTA compare to other antidepressants?

CAPLYTA offers a unique solution for patients who do not respond well to existing antidepressant therapies, displaying strong efficacy combined with low adverse effects compared to placebo.

What additional research is being conducted on CAPLYTA?

Intra-Cellular Therapies continues to explore CAPLYTA's effectiveness in treating psychiatric and neurological disorders, aiming to broaden its therapeutic applications.

Who can I contact for more information about Intra-Cellular Therapies?

For further inquiries about Intra-Cellular Therapies and CAPLYTA, you can reach out to Juan Sanchez, M.D., at 646-440-9333.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 154

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 67

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 158

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 337

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Impact of Proposed Tariffs on Europe's Automotive Sector

Updated Category News Views 226

Understanding the Impact of Proposed Tariffs on the Auto Industry The recent political climate and proposed tariffs from former U.S. President Donald Trump signal significant changes ahead for global automakers. European car manufacturers, including giants like Volkswagen and Stellantis, may feel the ripple effects more acutely than expected. This article explores how...

Continue Reading
Corning Incorporated Reports Impressive Year-End Results

Updated Category News Views 431

Corning Incorporated's Remarkable Financial Performance Corning Incorporated (NYSE: GLW) has announced impressive financial outcomes for the fourth quarter and full year 2024. The results reflect the company's successful implementation of its 'Springboard' plan and position Corning for continuous growth as it enters 2025. Outstanding Fourth-Quarter Growth In the fourth...

Continue Reading
AAV Gene Therapy Landscape: Transforming Retinal Disease Treatments

Updated Category News Views 199

Introducing the AAV Gene Therapy for Retinal Diseases Adeno-associated virus (AAV) has emerged as an essential tool in the realm of gene therapy, particularly for treating hereditary retinal diseases caused by mutations in critical genes such as RPE65, CEP290, and CHM. This gene therapy approach is designed to address unmet medical needs, offering hope for long-term or...

Continue Reading
Rayonier Declares 4th Quarter Dividend and Company Outlook

Updated Category News Views 76

Rayonier Announces Fourth-Quarter Dividend Rayonier Inc. (NYSE: RYN), a prominent timberland real estate investment trust (REIT), has declared an impressive quarterly cash dividend of $0.285 per common share. Shareholders can expect this dividend to be paid on December 31, 2024, to those recorded by December 17, 2024. This announcement reflects Rayonier's dedication to...

Continue Reading
Cango Inc. Reports Record Financial Growth and Future Plans

Updated Category News Views 177

Cango Inc. Financial Highlights Cango Inc. (NYSE: CANG) a prominent name in Bitcoin mining and automotive transaction services, has released its unaudited financial results demonstrating significant achievements in the financial year. Robust Fourth Quarter Performance The fourth quarter of 2024 was particularly fruitful for Cango, showcasing total revenues of RMB668...

Continue Reading